BioTime Spins Off OncoCyte
News Jan 05, 2016
The Company will ring the New York Stock Exchange Opening Bell on Wednesday, January 6, 2016 in celebration of it becoming a publicly traded company. A live webcast of the Opening Bell ceremony, will be available at https://livestream.com/NYSE/oncocyte beginning at 9:25 a.m. ET.
"OncoCyte is positioned to capitalize on liquid biopsy molecular diagnostics evolving to become the standard of care for a wide variety of diseases and conditions," commented William Annett, Chief Executive Officer of OncoCyte. "Becoming a publicly traded company is a key milestone in our development. We will continue to leverage the team’s diagnostics, commercial and public company expertise to achieve significant milestones in 2016 with the goal of maximizing shareholder value. These milestones will include preparation for the commercial launch of our first product, which subject to the successful completion of our R&D program will be a confirmatory diagnostic test for lung cancer."
On December 31, 2015, BioTime, Inc. (NYSE MKT:BTX), distributed approximately 4.75 million shares of OncoCyte common stock to its shareholders in the ratio of one share of OncoCyte common stock for every 20 BioTime common shares owned. There are now approximately 25.4 million shares outstanding of OncoCyte, of which BioTime owns 58.55%.
OncoCyte’s management team will publish a webcast presentation reviewing the Company’s strategies and opportunities on Tuesday, January 5th at 4 p.m. ET. To access the webcast go the "Events & Presentations" section located in the Company’s website on the Investors page at http://investors.oncocyte.com/events-and-presentations or tohttp://wsw.com/webcast/cc/oncocyte/
A replay of the event can be accessed on the website and will remain available for a year.
International Conference on Cell and Structural biology
Jul 15 - Jul 16, 2019
4th EuroSciCon Conference on Gynecologic Oncology and Reproductive Disorders
Jul 25 - Jul 26, 2019